TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06500923

Intervention type: OTHER
Intervention: Oral rehabilitation by means of implant-supported single unit crowns
Description: Surgery: Implant placement; Prothetic rehabilitation: single unit crown

Intervention type: OTHER
Intervention: Oral rehabilitation by means of implant-supported single unit crowns
Description: Surgery: Implant placement; Prothetic rehabilitation: single unit crown
Study: NCT04907227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Oral tablets
Study: NCT01616849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and 5-Fu combined with nimotuzumab
Description: DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week
Study: NCT03462459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin capsule, 125 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
Study: NCT00634595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10A
Description: E10A 1\*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
Study: NCT01681316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong injection
Description: A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study: NCT04076371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine-sertraline combination
Description: the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: only olanzapine
Description: the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone-sertraline combination
Description: the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: only risperidone
Description: the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone-sertraline combination
Description: the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: only paliperidone
Description: the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone-sertraline combination
Description: the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: only ziprasidone
Description: the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
Study: NCT02697565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Caregivers- Healthy Children Toolkit
Description: The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safety Curriculum
Description: Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
Study: NCT03572361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V3-MOMMO
Description: Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
Study: NCT03968250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Treating Fatigue
Description: The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed.
Study: NCT00597506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg Everolimus(RAD001) daily by mouth, days 1-28
Study: NCT04624776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
Study: NCT02893904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring
Description: Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring
Description: Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion
Description: Steady state effect site concentrations of remifentanil administrated to all patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion
Description: Steady state effect site concentrations of remifentanil administrated to all patients.
Study: NCT00525902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg delivered every 2 weeks by subcutaneous injection
Study: NCT02747849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
Study: NCT04100915

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT01549041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg daily in the evening
Description: The total daily dose of Asenapine will be given once daily in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asenapine 5 mg twice daily
Description: Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
Study: NCT01570634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Aluminosilicate Anti-Diarrheal (CASAD)
Description: CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
Study: NCT02947542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One-catheter concept
Description: Coronary angiography will be performed using the one-catheter concept.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One-catheter concept
Description: Coronary angiography will be performed using the one-catheter concept.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard catheter
Description: Coronary angiography will be performed using a standard catheter.
Study: NCT03005457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hemiparesis Therapy with VR
Description: An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hemiparesis Therapy with VR
Description: An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids
Study: NCT04308915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-based cognitive training
Description: A suite of 5 games is presented to the participants for training working memory
Study: NCT01594398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: 10 mg, po, q14 days, until progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: 10 mg, po, q14 days, until progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
Study: NCT00719914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptifibatide
Description: Intra-coronary injection, weight based, of eptifibatide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptifibatide
Description: Intra-coronary injection, based on weight, of eptifibatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Intra-coronary injection, weight based, of normal saline.
Study: NCT03333408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Oral Antibiotics (Clindamycin or Augmentin)
Description: Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
Study: NCT03603977

Intervention type: DRUG
Intervention: Lpv/r+3TC
Description: It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
Study: NCT03844594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide Injection
Description: Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
Study: NCT02356510

Intervention type: PROCEDURE
Intervention: Primary PCI

Intervention type: PROCEDURE
Intervention: Primary PCI
Study: NCT00727090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
Study: NCT04492072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Control
Study: NCT02712021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lycra suit and physiotherapy treatment
Description: Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy treatment
Description: All the children will be involved in regular physiotherapy treatment (2-3/week).
Study: NCT03457805

Intervention type: DEVICE
Group type: OTHER
Intervention: Prostatic Artery Embolization
Description: PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
Study: NCT01766414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-esterase inhibitor
Description: intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: intravenously
Study: NCT01692132

Intervention type: DRUG
Intervention: Prucalopride
Description: Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (\>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
Study: NCT03703843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTUS MONO
Description: Temporarily implant and activation of the medical device
Study: NCT01560585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
Study: NCT03121040

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vespa amino acid mixture
Description: 17 kinds of amino acids mixture in specific proportion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vespa amino acid mixture
Description: 17 kinds of amino acids mixture in specific proportion
Study: NCT03664453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone
Description: Omaveloxolone 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone
Description: Omaveloxolone 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone
Description: Omaveloxolone 50 mg capsules
Study: NCT04972539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-A51 Tab.
Description: Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-A51 Tab.
Description: Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
Study: NCT01252862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of two iStents through a small temporal clear corneal incision
Study: NCT01085136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator´s choice of chemotherapy
Description: BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
Study: NCT03981965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical activity as described previously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity as described previously.
Study: NCT04318639

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donepazil
Description: Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice.
Study: NCT04972539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R1 Tab. and A51R2 Tab.
Description: Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
Study: NCT03518970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Description: The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers.
Study: NCT02482064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible resin
Description: This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
Study: NCT02557373

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Bran + Vitamin A
Description: 100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
Study: NCT03702712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Relaxation
Description: This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of mindfulness training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Only
Description: This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of quiet rest.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Only
Description: This intervention will combine 20 minutes of mindfulness-based relaxation training followed by 20 minutes of quiet rest.
Study: NCT01474421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051
Description: Patients will receive AQW051 in a high dose once daily orally for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051
Description: Patients will receive AQW051 in a low dose once daily orally for 28 days.
Study: NCT01625689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIIL LAIV (live, trivalent seasonal influenza vaccine)
Description: Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
Study: NCT01429064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 administered orally daily
Study: NCT04447495

Intervention type: DIAGNOSTIC_TEST
Intervention: iAMP test
Description: The low-cost Atila BioSystems iAMP® COVID-19 Detection kit consists of a reaction buffer mix, primer mix, three sample buffer components, a positive and negative control, nasopharyngeal swabs, and sample collection vials. Each kit is suitable for 100 tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: iAMP test
Description: The low-cost Atila BioSystems iAMP® COVID-19 Detection kit consists of a reaction buffer mix, primer mix, three sample buffer components, a positive and negative control, nasopharyngeal swabs, and sample collection vials. Each kit is suitable for 100 tests.
Study: NCT03404349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for Adolescence Course
Description: There are 6 topics that will each be presented over 2 weeks for the 12 week intervention. Individuals will participate in a one to 1.5 hours, once a week intervention for 12weeks. Mindfulness is the practice of becoming aware of one's present-moment experience with compassion and openness as a basis for wise action. This curriculum is intended to strengthen attention and emotion regulation, cultivate wholesome emotions like gratitude and compassion, expand the repertoire of stress management skills, and help participants integrate mindfulness into daily life. Each lesson includes age-appropriate discussion, activities, and opportunities to practice mindfulness in a group setting.